Utilization of TandemHeart in cardiogenic shock: Insights from the THEME registry.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
washington; spokane; pshmc
BACKGROUND: TandemHeart has been demonstrated to improve hemodynamic and metabolic complications in cardiogenic shock (CS). Contemporary outcomes have not been reported.
OBJECTIVES: To evaluate the outcomes of the TandemHeart (LivaNova) in contemporary real-world use.
METHODS: We analyzed baseline characteristics, hemodynamic changes, and outcomes of all patients treated with TandemHeart who were enrolled in the THEME registry, a multicenter, prospective, observational study.
RESULTS: Between May 2015 and June 2019, 50 patients underwent implantation of the TandemHeart device. 22% of patients had TandemHeart implanted within 12 h, 32% within 24 h, and 52% within 48 h of CS diagnosis. Cardiac index (CI) was significantly improved 24 h after implantation (median change 1.0, interquartile range (IQR) (0.5-1.4 L/min/m
CONCLUSION: In a contemporary cohort of patients presenting in CS, the use of TandemHeart is associated with a 74% 30-day survival and a 66% 180-day survival.
Megaly, Michael; Gandolfo, Chaun; Zakhour, Samer; Jiang, Mei; Burgess, Kristie; Chetcuti, Stanley; Ragosta, Michael; Adler, Eric; Coletti, Andrew; O'Neill, Brian; Alaswad, Khaldoon; and Basir, Mir B, "Utilization of TandemHeart in cardiogenic shock: Insights from the THEME registry." (2023). Articles, Abstracts, and Reports. 7113.